ACADIA Pharmaceuticals (ACAD) AI Stock Analysis

• Market Cap: $3.60B
• Dividend Yield: N/A
• Average Volume (3M): 2.21M
• Price to Earnings (P/E): 16.0
• Beta (1Y): 1.18
• Revenue Growth: 14.41%
• EPS Growth: 627.78%
• Country: US
• Employees: 653
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): 0.16
• Shares Outstanding: 168,712,220
• 10 Day Avg. Volume: 2,790,591
• 30 Day Avg. Volume: 2,211,235
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 0.82
• Enterprise Value/Revenue: 2.88
• Enterprise Value/Gross Profit: 3.13
• Enterprise Value/Ebitda: 27.59
• 1Y Price Target: $29.76
• Price Target Upside: 40.11% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 18

• Rating: 68 Neutral
• Price Target: $23.00 ▲(8.29% Upside)

ACADIA Pharmaceuticals' strong financial performance and positive earnings call sentiment are the most significant factors driving the stock score. The company has demonstrated consistent revenue growth and efficient cost management. However, technical analysis indicates bearish momentum, which slightly offsets the positive financial outlook. The valuation is fair, but the lack of a dividend yield is a minor drawback.

Positive Factors

Revenue Growth

Consistent revenue growth indicates strong market demand and effective sales strategies, supporting long-term financial stability and expansion.

Pipeline Expansion

A robust pipeline with multiple late-stage trials enhances future growth prospects, diversifies revenue streams, and strengthens competitive position.

Cash Flow Generation

Strong cash flow generation supports operational flexibility, investment in R&D, and potential strategic acquisitions, underpinning long-term growth.

Negative Factors

Increased SG&A Expenses

Rising SG&A expenses can pressure margins and profitability, potentially limiting resources available for R&D and other growth initiatives.

Challenges in Clinical Trials

Clinical trial challenges can delay product development and approval timelines, impacting future revenue streams and competitive positioning.

Net Profit Margin Pressure

Decreasing net profit margins may indicate cost pressures or pricing challenges, potentially affecting long-term profitability and shareholder returns.

ACADIA Pharmaceuticals Business Overview & Revenue Model

Company Description

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It's pipeline include, pimavanserin, under phase 3 development for the treatment of Alzheimer's disease psychosis, and negative symptoms of schizophrenia; Trofinetide, a novel synthetic analog, under phase 3 development for the treatment of Rett syndrome; ACP-044, a novel first-in-class orally administered non-opioid analgesic, under phase 2 development for treating acute and chronic pain; and ACP-319, a positive allosteric modulator of the muscarinic receptor, under phase 1 development for treating schizophrenia and cognition in Alzheimer's. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.

How the Company Makes Money

ACADIA Pharmaceuticals generates revenue primarily through the sale of its flagship product, NUPLAZID. The company earns income from product sales to healthcare providers and pharmacies. Additionally, ACADIA may receive milestone payments and royalties from partnerships with other pharmaceutical companies involved in the development and commercialization of complementary therapies. The company also engages in research collaborations and licensing agreements that can provide additional revenue streams. Factors contributing to its earnings include the growth in demand for treatments for CNS disorders, successful marketing strategies, and potential new product approvals or expansions in indications for existing drugs.

ACADIA Pharmaceuticals Financial Statement Overview

Summary

ACADIA Pharmaceuticals shows strong financial health with consistent revenue growth, improved profitability, and positive cash flows. The balance sheet reflects stability with minimal leverage, and the overall financial performance indicates a positive outlook. Continued focus on maintaining profitability and managing debt levels will be crucial for sustaining this momentum.

Income Statement

The company has shown impressive revenue growth with a TTM (Trailing-Twelve-Months) revenue of $996.3 million, up from $957.8 million in the previous year, indicating a strong upward trajectory. The gross profit margin remains robust at approximately 92.0%, reflecting efficient cost management. Net profit margin has improved significantly, turning positive, which highlights enhanced profitability. EBIT and EBITDA margins are also positive, further emphasizing operational improvements.

Balance Sheet

ACADIA Pharmaceuticals demonstrates a healthy balance sheet with a low debt-to-equity ratio, suggesting prudent financial management. The equity ratio is high, indicating a strong reliance on equity financing. Return on Equity (ROE) is positive and improving, showcasing the company's ability to generate returns on shareholders' investments. However, the company's debt levels, while manageable, should be monitored as they have increased slightly.

Cash Flow

The company has achieved positive free cash flow, marking a significant improvement from previous years. Operating cash flow to net income ratio is healthy, suggesting effective cash management. While the free cash flow growth rate has declined slightly in the latest TTM period compared to the previous year, the overall cash flow position is solid, supporting future growth initiatives.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	1.02B	957.80M	726.44M	517.24M	484.14M	441.75M
Gross Profit	937.10M	875.96M	680.71M	507.07M	465.00M	421.20M
EBITDA	106.30M	100.16M	-67.83M	-221.57M	-167.09M	-286.59M
Net Income	222.16M	226.45M	-61.29M	-215.97M	-167.87M	-281.58M
Balance Sheet
Total Assets	1.23B	1.19B	748.96M	587.81M	700.12M	782.62M
Cash, Cash Equivalents and Short-Term Investments	762.00M	755.99M	438.87M	416.82M	520.71M	631.96M
Total Debt	44.60M	51.99M	57.20M	62.00M	56.13M	44.46M
Total Liabilities	403.17M	454.96M	317.20M	187.40M	159.23M	155.61M
Stockholders Equity	822.38M	732.79M	431.75M	400.41M	540.89M	627.01M
Cash Flow
Free Cash Flow	187.09M	157.20M	-23.35M	-114.03M	-126.78M	-143.75M
Operating Cash Flow	187.91M	157.72M	16.70M	-114.03M	-125.66M	-136.17M
Investing Cash Flow	-127.65M	-30.54M	32.00M	73.24M	-71.10M	192.51M
Financing Cash Flow	20.03M	6.84M	25.13M	8.20M	18.16M	81.00M

ACADIA Pharmaceuticals Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 21.24
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ACAD, the sentiment is Negative. The current price of 21.24 is below the 20-day moving average (MA) of 23.73, below the 50-day MA of 24.19, and above the 200-day MA of 19.99, indicating a neutral trend. The MACD of -0.87 indicates Positive momentum. The RSI at 32.58 is Neutral, neither overbought nor oversold. The STOCH value of 25.02 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ACAD.

ACADIA Pharmaceuticals Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
KRYS	78 Outperform	$5.12B	35.91	14.10%	―	116.09%	35.29%
ACAD	68 Neutral	$3.60B	16.04	33.18%	―	14.41%	627.78%
PTCT	58 Neutral	$4.82B	8.80	-304.62%	―	96.00%	―
ARWR	57 Neutral	$4.67B	-27.30	-323.27%	―	2816.21%	73.33%
ACLX	51 Neutral	$4.39B	-24.05	-23.60%	―	-60.63%	-216.87%
MLTX	41 Neutral	$401.12M	-2.57	―	―	―	-208.46%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

ACADIA Pharmaceuticals Corporate Events

Acadia Pharmaceuticals Wins Patent Case for NUPLAZID

On June 9, 2025, Acadia Pharmaceuticals announced that the U.S. Court of Appeals for the Federal Circuit upheld a previous decision by the U.S. District Court for the District of Delaware, confirming the validity of the company’s composition of matter patent for NUPLAZID® (pimavanserin). This legal victory against MSN Laboratories and its affiliate MSN Pharmaceuticals reinforces Acadia’s patent position, potentially strengthening its market position and providing assurance to stakeholders regarding the protection of its intellectual property.

The most recent analyst rating on (ACAD) stock is a Hold with a $20.00 price target. To see the full list of analyst forecasts on ACADIA Pharmaceuticals stock, see the ACAD Stock Forecast page.

Acadia Pharmaceuticals Holds 2025 Annual Stockholder Meeting

On May 29, 2025, Acadia Pharmaceuticals Inc. held its 2025 Annual Meeting of Stockholders, where three Class III directors were elected to the Board of Directors to serve until the 2028 Annual Meeting. Additionally, stockholders approved the compensation of the company’s named executive officers and ratified the appointment of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025.

The most recent analyst rating on (ACAD) stock is a Hold with a $20.00 price target. To see the full list of analyst forecasts on ACADIA Pharmaceuticals stock, see the ACAD Stock Forecast page.

ACADIA Pharmaceuticals Wins Favorable Patent Court Ruling

On May 15, 2025, ACADIA Pharmaceuticals entered into a 12-year lease agreement for new executive office space at 210 Carnegie Center in Princeton, New Jersey, with plans for commercial, research, and development activities. The company will pay an initial annual rent of $1,899,756, with incremental increases, and is responsible for operating expenses and property taxes. Additionally, ACADIA announced a favorable court ruling on May 16, 2025, regarding its formulation patent for NUPLAZID®, securing its position against competitors Aurobindo Pharma and MSN Laboratories.

The most recent analyst rating on (ACAD) stock is a Hold with a $20.00 price target. To see the full list of analyst forecasts on ACADIA Pharmaceuticals stock, see the ACAD Stock Forecast page.